TP53 abnormalities (del(17p) and/or TP53 mutations) have been associated with a reduced PFS in CLL patients treated with Venetoclax as a single agent, but they had no impact on response rates and rate of undetectable MRD [59,60] (Table 5). Here, TP53 is linked to B-cell chronic lymphocytic leukemia.